The impact of EGFR wild-type (EGFRwt) or EGFRvIII overexpression on the response to a pro-oxidant Trx/GSH co-targeting strategy to reach the lethal ROS threshold is currently unknown in GBM. This evidence concerns the gene EGFR and glioblastoma.